目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T61207 | |||
5-HT6/5-HT2A receptor ligand-1 (compound 33) is a dual antagonist for the 5-HT6 and 5-HT2A receptors. It exhibits a K i value of 2 nM and 11 nM for the respective receptors. This compound holds promise for research in neurological and psychiatric disorders [1]. | |||
T60923 | |||
Zelquistinel 用于研究抑郁、焦虑和其他相关精神疾病的研究。它是一种 N-甲基-D-天冬氨酸(NMDA)受体的部分激动剂。 | |||
T80971 | |||
TNIK-IN-6 (Compound 9) 是一种Traf2和Nck相互作用激酶(TNIK)的抑制剂,具有0.93 nM的IC50,对神经与精神疾病具有重要影响。 | |||
T62975 | |||
Haloperidol lactate 是一种有效的抗精神病药。Haloperidol lactate 具有潜力进行精神障碍的研究。Haloperidol lactate 能够用于急性和慢性精神分裂症和多发性秽语综合征。 | |||
T70787 | |||
AZD1446 tosylate, also known as TC-6683, is a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. AZD1446 tosylate showed favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and had been evaluated in phase 2 clinical trials as a treatment for Alzheimer's disease. | |||
T70196 | |||
AZD1446 HCl, also known as TC-6683, is a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. AZD1446 HCl showed favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and had been evaluated in phase 2 clinical trials as a treatment for Alzheimer's disease. | |||
T16507 | Casein Kinase | ||
PF-5006739 is an effective and selective inhibitor of CK1δ/ε (IC50s: 3.9 nM and 17.0 nM, respectively). PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selecti | |||
T60913 | |||
Aceprometazine (1664CB) 是具有口服活性的抗精神病剂。Aceprometazine 可用于精神类疾病研究,例如抑郁症。 | |||
T72246 | |||
Bicuculline methobromide 是选择性GABAA 受体拮抗剂,具IC50值为3 μM。该化合物可引起哺乳类动物阵挛性强直性惊厥,且能阻断Ca2+激活的钾通道,用于癫痫等精神疾病研究。 | |||
T38828 | |||
Mesdopetam (IRL790) is a dopamine D3 receptor antagonist with a Ki of 90 nM and an IC50 of 9.8 μM for the human recombinant D3 receptor. It exhibits psychomotor stabilizing properties and is utilized in the study of motor and psychiatric complications associated with Parkinson's disease. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-00357 | HNT/NTM Protein, Human, Recombinant (His) | Human | HEK293 | ||
NTM (Neurotrimin) is a Protein Coding gene. 4 alternatively spliced human isoforms have been reported. This gene encodes a member of the IgLON (LAMP, OBCAM, Ntm) family of immunoglobulin (Ig) domain-containing glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules. IgLONs have been associated with psychiatric disorders, intelligence, body weight, heart disease, and tumors. The encoded protein may promote neurite outgrowth and adhesion via a homophilic mechanism. Neurotrimin is a member of the family of neural cell adhesion molecules. Its expression pattern suggests that Ntm promotes axonal fasciculation, guides nerve fibers to specific targets and stabilizes synapses as it accumulates coincident with synaptogenesis. Diseases associated with NTM include Connective Tissue Disease and Jacobsen Syndrome.
|
|||||
TMPK-01200 | Nogo Receptor/RTN4R Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
NOGO Receptor 1 (RTN4R) regulates axonal growth, as well as axon regeneration after injury. The gene maps to the 22q11.2 schizophrenia susceptibility locus and is thus a strong functional and positional candidate gene.RTN4R may modulate the genetic risk or clinical expression of schizophrenia in a subset of patients and identify additional studies that will be necessary to clarify the role of RTN4R in psychiatric phenotypes.
|
|||||
TMPY-00397 | ITIH3 Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
ITIH3 (Inter-Alpha-Trypsin Inhibitor Heavy Chain 3) is a Protein Coding gene. This gene encodes the heavy chain subunit of the pre-alpha-trypsin inhibitor complex. This complex may stabilize the extracellular matrix through its ability to bind hyaluronic acid. ITIH3 is involved in the stabilization of the extracellular matrix. A polymorphism (rs2535629) of ITIH3 showed the strongest association signal with susceptibility to psychiatric disorders in Caucasian populations. Common single nucleotide polymorphisms (SNPs) in or near the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) gene have been repeatedly associated with schizophrenia and related psychiatric disorders in genome-wide association studies.ITIH3 may be a useful biomarker for the early detection of gastric cancer. Diseases associated with ITIH3 include Schizophrenia and Major Depressive Disorder.
|
|||||
TMPY-00198 | ITIH3 Protein, Human, Recombinant (His) | Human | HEK293 | ||
ITIH3 (Inter-Alpha-Trypsin Inhibitor Heavy Chain 3) is a Protein Coding gene. This gene encodes the heavy chain subunit of the pre-alpha-trypsin inhibitor complex. This complex may stabilize the extracellular matrix through its ability to bind hyaluronic acid. ITIH3 is involved in the stabilization of the extracellular matrix. A polymorphism (rs2535629) of ITIH3 showed the strongest association signal with susceptibility to psychiatric disorders in Caucasian populations. Common single nucleotide polymorphisms (SNPs) in or near the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) gene have been repeatedly associated with schizophrenia and related psychiatric disorders in genome-wide association studies.ITIH3 may be a useful biomarker for the early detection of gastric cancer. Diseases associated with ITIH3 include Schizophrenia and Major Depressive Disorder.
|
|||||
TMPK-00621 | CSPG5 Protein, Human, Recombinant (His) | Human | HEK293 | ||
Chondroitin sulfate proteoglycan 5 (CSPG-5), also known as neuroglycan C, has been previously associated to differentiation since it shapes neurite growth and synapse forming. CSPG-5 expression shifts in brain areas of the default mode network of suicide victims, which may reflect an impact in the pathogenesis of psychiatric diseases or support diagnostic power.
|
|||||
TMPK-01125 | FAM19A5 Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
FAM19A5 is a secretory protein that is predominantly expressed in the brain. Although the FAM19A5 gene has been found to be associated with neurological and/or psychiatric diseases, only limited information is available on its function in the brain. FAM19A5 plays a role in nervous system development from an early stage and increases its expression in response to pathological conditions in subsets of neurons and OPCs of the brain.
|
|||||
TMPK-00699 | FAM19A5 Protein, Human, Recombinant (His) | Human | E. coli | ||
FAM19A5 is a secretory protein that is predominantly expressed in the brain. Although the FAM19A5 gene has been found to be associated with neurological and/or psychiatric diseases, only limited information is available on its function in the brain. FAM19A5 plays a role in nervous system development from an early stage and increases its expression in response to pathological conditions in subsets of neurons and OPCs of the brain.
|
|||||
TMPY-00355 | HNT/NTM Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
NTM (Neurotrimin) is a Protein Coding gene. 4 alternatively spliced human isoforms have been reported. This gene encodes a member of the IgLON (LAMP, OBCAM, Ntm) family of immunoglobulin (Ig) domain-containing glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules. IgLONs have been associated with psychiatric disorders, intelligence, body weight, heart disease, and tumors. The encoded protein may promote neurite outgrowth and adhesion via a homophilic mechanism. Neurotrimin is a member of the family of neural cell adhesion molecules. Its expression pattern suggests that Ntm promotes axonal fasciculation, guides nerve fibers to specific targets and stabilizes synapses as it accumulates coincident with synaptogenesis. Diseases associated with NTM include Connective Tissue Disease and Jacobsen Syndrome.
|
|||||
TMPY-03991 | DBI Protein, Human, Recombinant (His) | Human | E. coli | ||
The diazepam binding inhibitor (DBI), alternatively known as the acyl-CoA binding protein (ACBP), is involved in multiple biological actions. The polypeptide binds to the peripheral, or mitochondrial, benzodiazepine receptor and facilitates transport of cholesterol to the inner membrane to stimulate steroid synthesis. Through this action, DBI indirectly modulates gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission. DBI can be postulated as a candidate gene for psychiatric phenotypes including anxiety, mood, and psychotic disorders. Diazepam Binding Inhibitor (DBI), also called acyl-CoA binding protein (ACBP), is a ubiquitously expressed protein originally identified based on its ability to displace diazepam from its binding site on the GABAA receptor. The mutant allele of the DBI was one of the risk factors for alcohol dependence as for the rs2276596 polymorphism.
|
|||||
TMPY-04033 | FGF-14 Protein, Canine, Recombinant | Canine | E. coli | ||
FGF14 is a member of the fibroblast growth factor (FGF) family. Members of this family possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF14 is probably involved in nervous system development and function. Defects in FGF14 are the cause of spinocerebellar ataxia type 27 (SCA27). It is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA27 is an autosomal dominant cerebellar ataxia. It is a slowly progressive disorder, with onset in late-childhood to early adulthood, characterized by ataxia with tremor, orofacial dyskinesia, psychiatric symptoms and cognitive deficits.
|
|||||
TMPY-01618 | GLO1 Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
Lactoylglutathione lyase, also known as Methylglyoxalase, Aldoketomutase, Glyoxalase I, Ketone-aldehyde mutase, S-D-lactoylglutathione methylglyoxal lyase and GLO1, is a member of the glyoxalase I family. GLO1 / Glyoxalase I is a ubiquitous cellular defense enzyme involved in the detoxification of methylglyoxal, a cytotoxic byproduct of glycolysis. Accumulative evidence suggests an important role of GLO1 expression in protection against methylglyoxal-dependent protein adduction and cellular damage associated with diabetes, cancer, and chronological aging. GLO1 / Glyoxalase I has been implicated in anxiety-like behavior in mice and in multiple psychiatric diseases in humans. GLO1 / Glyoxalase I catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. GLO1 / Glyoxalase I exists in three separable isoforms which originate from two alleles in the genome. These correspond to two homodimers and one heterodimer composed of two subunits showing different electrophoretic properties. GLO1 upregulation may play a functional role in glycolytic adaptations of cancer cells.
|
|||||
TMPY-02804 | FGF-14 Protein, Human, Recombinant (isoform 1B) | Human | E. coli | ||
FGF14 is a member of the fibroblast growth factor (FGF) family. Members of this family possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF14 is probably involved in nervous system development and function. Defects in FGF14 are the cause of spinocerebellar ataxia type 27 (SCA27). It is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA27 is an autosomal dominant cerebellar ataxia. It is a slowly progressive disorder, with onset in late-childhood to early adulthood, characterized by ataxia with tremor, orofacial dyskinesia, psychiatric symptoms and cognitive deficits.
|
|||||
TMPY-01215 | NAALADL1 Protein, Human, Recombinant (His) | Human | HEK293 | ||
N-acetylated-alpha-linked acidic dipeptidase-like protein, also known as NAALADL1, NAALADase L, and Ileal dipeptidyl-peptidase, is a Single-pass type II membrane protein and a member of the peptidase M28 family and M28B subfamily. NAALADase L is mainly expressed in the distal small intestine. It is also expressed in the spleen and testis and Weakly expressed in the brain, locating mainly to the brain stem, amygdala, thalamus, and ventral striatum. NAALADase L is a chloride-activated, membrane-bound, metallopeptidase that cleaves the endogenous neuropeptide N-acetyl-aspartyl-glutamate (NAAG). NAAG acts as a partial NMDA agonist as well as a full agonist at the presynaptic metabotropic glutamate receptor 3 (mGluR3), where it acts to reduce glutamate release. NAALADase L also exhibits a dipeptidyl-peptidase IV type activity. NAALADase inhibition may be a novel therapeutic approach to reduce or inhibit heightened aggressiveness, and possibly to treat aggressive behavior associated with psychiatric disorders.
|
|||||
TMPY-02668 | NAALADL1 Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
N-acetylated-alpha-linked acidic dipeptidase-like protein, also known as NAALADL1, NAALADase L, and Ileal dipeptidyl-peptidase, is a Single-pass type II membrane protein and a member of the peptidase M28 family and M28B subfamily. NAALADase L is mainly expressed in the distal small intestine. It is also expressed in the spleen and testis and Weakly expressed in the brain, locating mainly to the brain stem, amygdala, thalamus, and ventral striatum. NAALADase L is a chloride-activated, membrane-bound, metallopeptidase that cleaves the endogenous neuropeptide N-acetyl-aspartyl-glutamate (NAAG). NAAG acts as a partial NMDA agonist as well as a full agonist at the presynaptic metabotropic glutamate receptor 3 (mGluR3), where it acts to reduce glutamate release. NAALADase L also exhibits a dipeptidyl-peptidase IV type activity. NAALADase inhibition may be a novel therapeutic approach to reduce or inhibit heightened aggressiveness, and possibly to treat aggressive behavior associated with psychiatric disorders.
|